Vaishali Pharma Limited - Asset Resilience Ratio
Vaishali Pharma Limited (VAISHALI) has an Asset Resilience Ratio of 25.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read VAISHALI total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Vaishali Pharma Limited's Asset Resilience Ratio has changed over time. See what is Vaishali Pharma Limited's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vaishali Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Vaishali Pharma Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs10.46 Million | 0.86% |
| Short-term Investments | Rs298.02 Million | 24.44% |
| Total Liquid Assets | Rs308.48 Million | 25.30% |
Asset Resilience Insights
- Very High Liquidity: Vaishali Pharma Limited maintains exceptional liquid asset reserves at 25.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vaishali Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Vaishali Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Vaishali Pharma Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Vaishali Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 27.42% | Rs301.23 Million ≈ $3.26 Million |
Rs1.10 Billion ≈ $11.88 Million |
+25.11pp |
| 2024-03-31 | 2.31% | Rs18.50 Million ≈ $200.09K |
Rs799.56 Million ≈ $8.65 Million |
-14.01pp |
| 2023-03-31 | 16.32% | Rs128.79 Million ≈ $1.39 Million |
Rs789.07 Million ≈ $8.53 Million |
+0.13pp |
| 2022-03-31 | 16.19% | Rs132.16 Million ≈ $1.43 Million |
Rs816.24 Million ≈ $8.83 Million |
+1.93pp |
| 2021-03-31 | 14.26% | Rs122.79 Million ≈ $1.33 Million |
Rs861.23 Million ≈ $9.31 Million |
+16.90pp |
| 2020-03-31 | -2.64% | Rs-17.50 Million ≈ $-189.22K |
Rs662.04 Million ≈ $7.16 Million |
+1.58pp |
| 2019-03-31 | -4.22% | Rs-29.00 Million ≈ $-313.66K |
Rs687.51 Million ≈ $7.44 Million |
-19.56pp |
| 2018-03-31 | 15.34% | Rs98.66 Million ≈ $1.07 Million |
Rs643.23 Million ≈ $6.96 Million |
+15.78pp |
| 2017-03-31 | -0.44% | Rs-1.98 Million ≈ $-21.40K |
Rs446.49 Million ≈ $4.83 Million |
-1.02pp |
| 2016-03-31 | 0.58% | Rs2.88 Million ≈ $31.16K |
Rs497.73 Million ≈ $5.38 Million |
-- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more